Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Breast Neoplasms 6Neuroendocrine Tumors 5Neoplasm Metastasis 3Carcinoma, Renal Cell 3Tuberous Sclerosis 2Triple Negative Breast Neoplasms 2Recurrence 2Glioma 2Endometrial Neoplasms 2Adenoma, Islet Cell 2von Hippel-Lindau Disease 1Vascular Malformations 1Unilateral Breast Neoplasms 1Thymus Neoplasms 1Seizures 1Sarcoma, Kaposi 1Sarcoma 1Nevus 1Myelodysplastic Syndromes 1Multiple Endocrine Neoplasia Type 1 1Metastatic Digestive System Neuroendocrine Tumor G1 1Meningioma 1Lymphangioma 1Liposarcoma 1Leukemia, Myeloid, Acute 1Leiomyosarcoma 1Kidney Neoplasms 1Hemangioma 1Hemangioendothelioma 1Hamartoma Syndrome, Multiple 1

Interventions

fludarabine 25Cyclophosphamide 20Azacitidine 20venetoclax 18Specimen Handling 18fludarabine phosphate 17Mycophenolic Acid 14Melphalan 14Busulfan 14Biopsy 14Whole-Body Irradiation 13Tacrolimus 12Cytarabine 12Granulocyte Colony-Stimulating Factor 10decitabine and cedazuridine drug combination 9Decitabine 9Stem Cell Transplantation 8Sirolimus 8Injections 8Filgrastim 8Cyclosporine 8Peripheral Blood Stem Cell Transplantation 7Thiotepa 6ruxolitinib 5X-Rays 5Idarubicin 5Magnetic Resonance Spectroscopy 4Cladribine 4CPX-351 411-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × Everolimus × 90 days × Clear all
NCT00819546 2026-03-25

RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
29 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡